Niraxostat

Cat. No.: HY-14669

CAS No.: 206884-98-2

Molecular Formula: $C_{16}H_{17}N_3O_3$

Molecular Weight: 299.32

Target: Xanthine Oxidase

Pathway: Metabolic Enzyme/Protease

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

Niraxostat (Y-700; Piraxostat) is an orally active xanthine oxidoreductase (XOR) inhibitor used in the study of hyperuricemia and other diseases in which XOR may be involved[1].

In Vivo

Niraxostat (Y-700; 1 mg/kg) has high oral bioavailability (84.1%) and is almost not excreted through the kidneys. It is mainly eliminated through the liver[1].

Niraxostat (Y- 700; 1-10 mg/kg; oral; single dose) dose-dependently reduces plasma urate levels in oxonate-treated rats [1].

Niraxostat (Y-700 ; 0.3-3 mg/kg; Oral; Single dose) In normal rats, dose-dependently reduces urinary excretion of urate and allantoin while increasing excretion of hypoxanthine and xanthine [1].

Pharmacokinetic Analysis of Niraxostat (Y-700) in normal rats[1]

Route	Dose (mg/kg)	t_{max} (h)	C_{max} (μg/ml)	$AUC_{0-\infty}$ (μg/h/ml)	$t_{1/2}$ (h)
PO	0.3	0.5	0.43	2.07	5.0
PO	1	0.3	1.8	7.01	3.2
PO	3	0.5	6.49	30.31	2.7
IV	1	/	3.97	8.34	2.5

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Fukunari A, et al. Y-700 [1-[3-Cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic acid]: a potent xanthine oxidoreductase inhibitor with hepatic excretion. J Pharmacol Exp Ther. 2004 Nov;311(2):519-28.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA